<h2 id="introduction">Introduction</h2> <p>The Abbreviated New Drug Application (ANDA) is a crucial pathway for generic drugs to gain FDA approval. Unlike the New Drug Application (NDA) process for br...
<h2 id="introduction">Introduction</h2> <p>The Abbreviated New Drug Application (ANDA) is a crucial pathway for generic drugs to gain FDA approval. Unlike the New Drug Application (NDA) process for brand-name drugs, which requires extensive clinical trials, the focus of the ANDA process is on demonstrating bioequivalence to a previously approved reference listed drug (RLD). By delivering the same active ingredient at the same rate and extent as the RLD, generic drugs can provide safe and effective alternatives to their brand-name counterparts.</p> <p>This article explores the key components of an ANDA submission package, the ANDA submission process, regulatory requirements and guidelines, changes to an approved ANDA, postmarketing reporting and compliance, facility fees and self-identification, labeling and advertising requirements, common deficiencies, best practices for avoiding them, and the role of regulatory consulting in ANDA approval. Nav…